Literature DB >> 17475854

Antigenic targeting of the human mannose receptor induces tumor immunity.

Li-Zhen He1, Andrea Crocker, Janine Lee, Jose Mendoza-Ramirez, Xi-Tao Wang, Laura A Vitale, Thomas O'Neill, Chris Petromilli, Hui-Fen Zhang, Joe Lopez, Dan Rohrer, Tibor Keler, Raphael Clynes.   

Abstract

Pattern recognition receptors are preferentially expressed on APCs allowing selective uptake of pathogens for the initiation of antimicrobial immunity. In particular, C-type lectin receptors, including the mannose receptor (MR), facilitate APC-mediated adsorptive endocytosis of microbial glyconjugates. We have investigated the potential of antigenic targeting to the MR as a means to induce Ag-specific humoral and cellular immunity. hMR transgenic (hMR Tg) mice were generated to allow specific targeting with the anti-hMR Ab, B11. We show that hMR targeting induced both humoral and cellular antigenic specific immunity. Immunization of hMR Tg mice with B11 mAbs induced potent humoral responses independent of adjuvant. Injection of hMR Tg mice with mouse anti-hMR Ab clone 19.2 elicited anti-Id-specific humoral immunity while non-Tg mice were unresponsive. B11-OVA fusion proteins (B11-OVA) were efficiently presented to OVA-specific CD4 and CD8 T cells in MR Tg, but not in non-Tg, mice. Effector differentiation of responding T cells in MR Tg mice was significantly enhanced with concomitant immunization with the TLR agonist, CpG. Administration of both CpG and B11-OVA to hMR Tg mice induced OVA-specific tumor immunity while WT mice remained unprotected. These studies support the clinical development of immunotherapeutic approaches in cancer using pattern recognition receptor targeting systems for the selective delivery of tumor Ags to APCs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475854     DOI: 10.4049/jimmunol.178.10.6259

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

Review 1.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

2.  Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.

Authors:  Eynav Klechevsky; Anne-Laure Flamar; Yanying Cao; Jean-Philippe Blanck; Maochang Liu; Amy O'Bar; Olivier Agouna-Deciat; Peter Klucar; Luann Thompson-Snipes; Sandra Zurawski; Yoram Reiter; A Karolina Palucka; Gerard Zurawski; Jacques Banchereau
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

3.  Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.

Authors:  Michael A Morse; Robert Chapman; John Powderly; Kimberly Blackwell; Tibor Keler; Jennifer Green; Renee Riggs; Li-Zhen He; Venky Ramakrishna; Laura Vitale; Biwei Zhao; Stephen A Butler; Amy Hobeika; Takuya Osada; Thomas Davis; Timothy Clay; H Kim Lyerly
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

Review 4.  C-type lectin receptor-induced NF-κB activation in innate immune and inflammatory responses.

Authors:  Lara M Kingeter; Xin Lin
Journal:  Cell Mol Immunol       Date:  2012-01-16       Impact factor: 11.530

Review 5.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 6.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

Review 7.  The danger model: questioning an unconvincing theory.

Authors:  Szczepan Józefowski
Journal:  Immunol Cell Biol       Date:  2015-07-28       Impact factor: 5.126

Review 8.  Improving vaccines by targeting antigens to dendritic cells.

Authors:  Ken Shortman; Mireille H Lahoud; Irina Caminschi
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

Review 9.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

10.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.